Trending News

FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment

FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment

For Immediate Release: October 20, 2026 The U.S. Food and Drug Administration today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. Hibsago is...

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

For Immediate Release: October 20, 2026 The U.S. Food and Drug Administration yesterday approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access...

The Hidden Long-Term Effects of Chemotherapy in Older Breast Cancer Survivors

The Hidden Long-Term Effects of Chemotherapy in Older Breast Cancer Survivors

Thanks to advances in breast cancer treatment, more women are living longer after their diagnosis than ever before. But as survival rates improve, researchers are paying closer attention to what happens after treatment ends. For many survivors, the effects of chemotherapy do not disappear when the last infusion is completed. A recent study examined older breast...